IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund reduced its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 70.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,500 shares of the company's stock after selling 34,500 shares during the period. Healthcare of Ontario Pension Plan Trust Fund's holdings in IDEAYA Biosciences were worth $509,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDYA. First Light Asset Management LLC purchased a new position in IDEAYA Biosciences in the fourth quarter valued at approximately $12,299,000. Price T Rowe Associates Inc. MD lifted its position in IDEAYA Biosciences by 17.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,566,278 shares of the company's stock valued at $126,889,000 after acquiring an additional 535,909 shares during the last quarter. Virtu Financial LLC acquired a new position in IDEAYA Biosciences in the fourth quarter valued at $582,000. Wellington Management Group LLP purchased a new position in shares of IDEAYA Biosciences during the fourth quarter worth about $2,988,000. Finally, Fisher Asset Management LLC increased its position in shares of IDEAYA Biosciences by 1,611.9% during the fourth quarter. Fisher Asset Management LLC now owns 539,676 shares of the company's stock worth $19,202,000 after purchasing an additional 508,151 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Trading Down 5.1 %

Shares of IDYA stock traded down $1.58 during mid-day trading on Wednesday, reaching $29.48. The stock had a trading volume of 681,673 shares, compared to its average volume of 863,985. The company has a market cap of $2.23 billion, a P/E ratio of -14.67 and a beta of 0.82. IDEAYA Biosciences, Inc. has a 12-month low of $23.41 and a 12-month high of $47.74. The business has a 50-day simple moving average of $36.25 and a 200 day simple moving average of $38.50.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.52%. During the same period in the previous year, the business posted ($0.50) earnings per share. Research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. dropped their price target on IDEAYA Biosciences from $69.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Mizuho started coverage on shares of IDEAYA Biosciences in a report on Monday, July 8th. They issued an "outperform" rating and a $50.00 target price on the stock. Lifesci Capital upgraded shares of IDEAYA Biosciences to a "strong-buy" rating in a research note on Monday, July 29th. Wedbush lowered their price objective on shares of IDEAYA Biosciences from $54.00 to $52.00 and set an "outperform" rating on the stock in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $56.00.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.